Online inquiry

IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11871MR)

This product GTTS-WQ11871MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GUCY2C gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_004963.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2984
UniProt ID P25092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11871MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5981MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CLLB8
GTTS-WQ7253MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FP-1302
GTTS-WQ4829MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ626MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ5989MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 095
GTTS-WQ11303MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-522
GTTS-WQ1891MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ5148MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW